F M Investments LLC Has $4.09 Million Stock Holdings in Haemonetics Co. (NYSE:HAE)

F M Investments LLC decreased its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 48.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 52,339 shares of the medical instruments supplier's stock after selling 50,133 shares during the quarter. F M Investments LLC owned 0.10% of Haemonetics worth $4,087,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in HAE. Raymond James Financial Inc. acquired a new stake in shares of Haemonetics in the fourth quarter valued at $19,002,000. Envestnet Asset Management Inc. increased its position in Haemonetics by 9.6% during the 4th quarter. Envestnet Asset Management Inc. now owns 48,068 shares of the medical instruments supplier's stock worth $3,753,000 after purchasing an additional 4,217 shares during the period. Riverwater Partners LLC lifted its stake in shares of Haemonetics by 12.4% in the fourth quarter. Riverwater Partners LLC now owns 50,379 shares of the medical instruments supplier's stock valued at $3,934,000 after purchasing an additional 5,538 shares during the period. Groupama Asset Managment purchased a new position in shares of Haemonetics in the fourth quarter valued at $19,520,000. Finally, May Hill Capital LLC acquired a new position in shares of Haemonetics during the 4th quarter worth approximately $1,399,000. Institutional investors and hedge funds own 99.67% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on HAE shares. Needham & Company LLC dropped their target price on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a research report on Tuesday, March 18th. StockNews.com lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. Bank of America lowered shares of Haemonetics from a "neutral" rating to an "underperform" rating and reduced their target price for the company from $95.00 to $68.00 in a report on Friday, February 7th. Barrington Research dropped their price objective on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Finally, JMP Securities decreased their price target on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $101.22.

Haemonetics Stock Down 0.5 %

Haemonetics stock traded down $0.30 during mid-day trading on Wednesday, hitting $58.00. 122,760 shares of the company's stock were exchanged, compared to its average volume of 686,859. The stock has a market cap of $2.91 billion, a P/E ratio of 22.83, a P/E/G ratio of 1.11 and a beta of 0.41. Haemonetics Co. has a 1-year low of $55.30 and a 1-year high of $97.97. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The stock has a 50 day moving average of $63.27 and a two-hundred day moving average of $73.19.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.